Lornestin 1,50 mg Tablet
PDF Leaflet Revision Date: 02 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Emergency contraception within 72 hours of unprotected intercourse.
Dosage (summary)
1.5 mg orally, taken within 72 hours after unprotected intercourse.
Special Populations
- Not recommended in children
- Obese women may have reduced efficacy
Pregnancy & Breastfeeding
Contraindicated in pregnancy; minimal transfer to breast milk; avoid nursing for 8 hours post-dose.
Key Drug Interactions
- CYP3A4 inducers reduce efficacy
- Antibiotics may reduce efficacy
Contraindications
- Hypersensitivity to levonorgestrel
- Severe hepatic insufficiency
- Pregnancy
- Uncontrolled depression
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Lower abdominal pain
Counselling Points
- Take as soon as possible after unprotected intercourse
- Use barrier method until next period
- Consult doctor if mood changes occur
Serious warnings
- Does not prevent pregnancy in all cases
- Consider ectopic pregnancy if pregnancy occurs post-treatment
Important Disclaimer
The Lornestin 1,50 mg Tablet professional information leaflet below is the property of Trinity Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
